H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Lifeward to $4.50 from $13 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's operational changes, regulatory wins and changes in payor dynamics underway bode well for future growth.
